Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $39.41, demonstrating a -0.76% swing from the preceding day's closing price. This change lagged the S&P 500's 0.67% gain on the day.

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading ... Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, lost 0.51%. The company's stock has climbed by 6.22% ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49 ... and the technology-centric Nasdaq increased by 1.35%. Prior to today's trading, shares of the company had lost ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Below is Validea's guru fundamental report for CRISPR THERAPEUTICS AG (CRSP). Of the 22 guru strategies we follow, CRSP rates highest using our Value Investor model based on the published strategy ...